Damaged myocardial tissue and associated immune cells

"Damaged myocardial tissue and associated immune cells" refers to the pathological and reparative processes that occur in heart muscle after injury (such as myocardial infarction), during which damaged cardiomyocytes trigger an immune response. This involves rapid recruitment and activation of various immune cell types including monocytes, macrophages (both resident and infiltrating), neutrophils, eosinophils, dendritic cells, and T cells. In the acute phase, inflammatory cells clear necrotic tissue; later, anti-inflammatory and reparative cells facilitate scar formation and tissue remodeling. The molecular landscape is characterized by dynamic shifts in cytokines (IL-1β, TNF-α, IL-10, TGF-β), chemokine-mediated recruitment (notably through the CCL2/CCR2 axis), and changes in immune cell phenotype (M1 to M2 macrophage polarization, N1 to N2 neutrophils). Interventions and drugs that target individual cell types or pathways (e.g., immunomodulators, specific cytokine or chemokine inhibitors) can influence outcome, but the tissue-immune complex itself is not a discrete molecular entity and therefore not a standard "therapeutic target"[1][2][3][4][5]. This entry is not a standard molecular target such as a receptor, enzyme, or transporter, but rather a dynamic microenvironment involving multiple cellular and molecular players, making it inappropriate for use as a single canonical drug target.

Other names

Damaged cardiac tissue and associated immune cellsPost-infarct myocardium and infiltrating leukocytesInfarcted heart immune microenvironment

Immunomodulation (e.g., shifting macrophage polarization from pro-inflammatory to reparative phenotypes) Depletion or blockade of specific leukocyte subsets (e.g., monocyte or neutrophil targeting) Inhibition of chemokine or cytokine signaling (e.g., CCR2/CCL2 axis blockade) Modulation of extracellular matrix remodeling